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Abstract
Glioblastoma cells express a mutant EGF receptor (EGFRvIII) that has constitutive tyrosine kinase activity and enhances
their tumorigenicity. Here we show that EGFRvIII promotes constitutive phosphorylation of extracellular regulated kinases
(ERKs) in glioblastoma cells in the absence of EGF. EGFRvIII also promoted constitutive activation of phosphoinositide 3-
kinase in these cells, as assessed by phosphorylation of protein kinase B/akt. As expected, phosphorylation of protein kinase
B/akt was blocked by the phosphoinositide 3-kinase inhibitors wortmannin and LY294002. Less expectedly, we found that
this treatment also blocked EGFRvIII-induced phosphorylation of ERKs. In contrast, ERK phosphorylation induced by
EGF-activated normal EGF receptor in the same cells was largely unaffected by treatment with phosphoinositide 3-kinase
inhibitors. This difference in behavior between the normal receptor and EGFRvIII was not due to differences in the levels of
activated EGFRvIII and wild-type EGF receptor, as the two types of receptor were tyrosine phosphorylated to a similar
extent under the experimental conditions used. EGFRvIII activation of ERKs was also sensitive to the phospholipase C
inhibitor U73122, whereas ERK activation by normal EGF receptor was not. These results show that EGFRvIII and wild-
type EGF receptor preferentially use different signaling pathways to induce ERK phosphorylation. The different
mechanisms of ERK activation used by normal and mutant EGF receptors may be important in understanding the potent
tumorigenic activity of EGFRvIII. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
A mutant EGF receptor, EGFRvIII, which lacks
the regions coded for by exons 2^7 of the EGF re-
ceptor gene, has been detected in carcinoma of the
brain, breast [1,2], lung [3], prostate [4] and ovary [2].
EGFRvIII has been studied in most detail in glio-
blastoma, where it is reported to be present in 24^
52% of cases [1,5]. Expression of EGFRvIII is main-
tained when human glioblastoma cells are grown as
xenografts, but is lost when the cells are grown in
tissue culture [6]. When EGFRvIII is reintroduced
into glioblastoma cell lines, it greatly enhances their
tumorigenicity in vivo [7]. This correlates with both
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increased proliferation and decreased apoptosis with-
in the tumors [8].
The molecular mechanisms by which EGFRvIII
promotes aggressive in vivo growth of glioblastomas
have not been fully elucidated. In glioblastoma cells,
EGFRvIII has been shown to be constitutively phos-
phorylated on tyrosine residues [9]. Also, EGFRvIII
has been shown to constitutively associate with the
adapter proteins Shc and Grb2 and to increase levels
of ras in the GTP-bound form [10]. In addition, there
is evidence that EGFRvIII increases the activity of
extracellular regulated kinases (ERKs) [11], which
are widely recognized as having an important role
in the regulation of proliferation and apoptosis
[12]. However, the mechanism by which EGFRvIII
activates ERKs has not been established. While a
pathway in which ras activates a protein kinase cas-
cade consisting of raf-1, MEK and ERK is well es-
tablished [13], numerous questions remain about the
regulation of this pathway, and the nature and role
of alternate pathways leading to ERK activation. In
particular, one question that has not been resolved is
the role of phosphoinositide (PI) 3-kinase in regulat-
ing this pathway. There have been a number of re-
ports that inhibitors of PI-3 kinase block ERK acti-
vation by tyrosine kinase receptors in some cell
types, but not in others. With respect to the EGF
receptor, it has been reported that in parietal cells
the PI 3-kinase inhibitor wortmannin had no e¡ect
on EGF-induced activation of ERKs [14]. In COS
cells, it has been reported that EGF-induced activa-
tion of ERKs is wortmannin-sensitive, but only when
very low levels of EGF receptors are activated [15].
Again the exact mechanism of this inhibition is un-
known, although there is evidence that it occurs both
above and below the level of ras [15].
In this report we show that EGFRvIII induces the
constitutive phosphorylation of ERKs in glioblasto-
ma cells. This phosphorylation was blocked by two
di¡erent PI 3-kinase inhibitors, and also by a phos-
pholipase C inhibitor. However, ERK phosphoryla-
tion induced by normal EGF receptors in the same
cells was not a¡ected by these inhibitors. This di¡er-
ence was detected under conditions where levels of
activated, tyrosine-phosphorylated normal EGF re-
ceptor and EGFRvIII were similar. Thus the two
types of receptors use di¡erent mechanisms to acti-
vate ERKs.
2. Materials and methods
2.1. Antibodies and inhibitors
Phospho-p44/42 MAP kinase (Thr202/Tyr204)
E10 monoclonal antibody, phospho-Akt (Ser 473)
monoclonal antibody and PD98059 were from New-
England Biolabs (Beverly, MA). Pan-ERK anti-
body and anti-phosphotyrosine antibody PY20
were from Transduction Laboratories (Lexington,
KY). Akt1(C20) goat polyclonal antibody and
EGFR(1005) rabbit polyclonal antibody were from
Santa Cruz Biotechnology (Santa Cruz, CA). Wort-
mannin, U73122 and U73343 were from Sigma-Al-
drich Canada (Oakville, ON). LY 294002 was from
Calbiochem-Novabiochem (La Jolla, CA). EGF was
from Gibco-BRL (Rockville, MD).
2.2. Cell culture
U87MG glioblastoma cells and U87MGvEGFR
cells were obtained from Dr W. Cavenee (Ludwig
Institute for Cancer Research, La Jolla, CA).
U87MGvEGFR were originally made by transduc-
tion of U87MG cells with a retroviral vector contain-
ing the coding sequence of EGFRvIII, followed by
£uorescence-activated cell sorting for high expressors
[7]. U87MGvEGFR cells have normal p53, but are
mutated in the PTEN tumor suppressor and at the
INK4a locus, expressing neither p16INK4a nor
p19ARF [16]. This set of mutations resembles those
seen in primary tumor samples taken from de novo
glioblastoma multiforme patients [17]. Cells were
routinely cultured in DMEM supplemented with
2 mM glutamine, 100 units/ml penicillin, 100 Wg/ml
streptomycin and 10% fetal calf serum. For Western
blot samples, cells were plated in medium containing
10% fetal calf serum at 2U106 per 100-mm plate or
3U105 per 35-mm plate, and then switched to me-
dium containing 0.5% fetal calf serum the following
day. Inhibitor treatments and collection of samples
for Western blotting were carried out two days after
plating.
2.3. Western blotting
Cells in monolayer culture were washed twice in
ice-cold PBS and then lysed by the addition of hot
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lysis bu¡er (5 mM Tris (pH 6.8), 4% sodium dodecyl
sulfate, 2% glycerol, 0.2 M dithiothreitol). Samples
were then scraped into microfuge tubes, boiled for 10
min, sonicated, and boiled again for 5 min. Protein
concentrations were measured using the Bio-Rad
Protein assay (Bio-Rad Laboratories, Hercules,
CA). Samples were run on 12% sodium dodecyl sul-
fate^polyacrylamide gels and transferred to nitrocel-
lulose. After transfer, blots were stained for total
protein with a solution of 1% amido black in 50%
methanol, 10% acetic acid. This served as a control
that equal amounts of total protein were loaded and
transferred per lane. Blots were then washed with
H2O, blocked with 5% skimmed milk powder in
TBST (10 mM Tris^HCl (pH 7.6), 150 mM NaCl,
0.05% Tween-20) for 1^2 h and incubated with the
appropriate primary antibody at dilutions recom-
mended by the supplier. Blots were then washed,
incubated with second antibody (goat anti-mouse
from Bio-Rad Laboratories) and washed again. Blots
were developed using the LumiGLO chemilumines-
cence substrate kit (Kirkegaard and Perry Laborato-
ries, Gaithersburg, MD).
3. Results
3.1. EGFRvIII induces constitutive ERK
phosphorylation
We ¢rst established that EGFRvIII induced con-
stitutive phosphorylation of ERKs in glioblastoma
cells. U87MGvEGFR and U87MG cells were incu-
bated overnight in 0.5% fetal calf serum and then
treated for 1^2 h with the EGF receptor tyrosine
kinase inhibitor AG1478 or DMSO as a control.
AG1478 has been shown to be highly speci¢c for
the EGF receptor tyrosine kinase [18], and has also
been shown to inhibit EGFRvIII tyrosine kinase ac-
tivity [19]. Total cell lysates from treated cells were
prepared as described in Section 2, and analyzed by
Western blotting (Fig. 1). Blots were probed with an
antiserum recognizing both ERK1 and ERK2 (pan
ERK), and antiserum that recognizes the same pro-
teins only when they are phosphorylated at threo-
nine-202 and tyrosine-204 (numbering based on hu-
man ERK1 sequence). With pan ERK antiserum, a
band was detected of the MW expected for ERK2,
and with longer exposures a second slightly higher
MW ERK1 band was detected. Levels of ERKs were
una¡ected by treatment with AG1478 and were the
same in both U87MGvEGFR and U87MG cells.
When blots were probed with a monoclonal antibody
speci¢c for phosphorylated ERKs, a strong doublet
was detected in U87MGvEGFR cells. This intensity
of this doublet was reduced to almost undetectable
levels by treatment with AG1478. AG1478 was e¡ec-
tive in this regard at concentrations as low as 1 WM
(Fig. 1B) and inhibition was apparent after as little
as 15 min of treatment (not shown).
Phosphorylated ERKs were also detected in
U87MG cells. However, levels of phosphorylated
ERKs in these cells were completely una¡ected by
treatment with AG1478. The ERK phosphorylation
is therefore not due to autocrine activation of normal
EGF receptor in these cells. Consistent with this,
phosphorylated ERK levels were also una¡ected by
incubation of cells with an antibody that blocks
binding of EGF and TGFK to wild-type EGF recep-
tor (data not shown). Levels of phosphorylated
ERKs in U87MG were on average slightly lower
Fig. 1. (A) AG1478 treatment of U87MGvEGFR and U87MG
cells. U87MGvEGFR (lanes a,b) and U87MG cells (lanes c,d)
were treated for 2 h with either DMSO (lanes a,c) or 100 WM
AG 1478 (lanes b,d). Total cell extracts were harvested and an-
alyzed by Western blotting for either phosphorylated ERK
(pERK), total ERK protein, phosphotyrosine, phosphorylated
PKB or total PKB protein. DMSO at the concentrations used
in this or the following experiments had no e¡ect on pERK or
ERK levels. (B) U87MGvEGFR cells were treated with 0 WM
(lane a), 0.1 WM (lane b), 1 WM (lane c) or 10 WM (lane d)
AG1478 for 1 h and analyzed as above.
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than in U87MGvEGFR cells, consistent with the
work of Wu et al. which showed increased kinase
activity of ERK1/2 in U87MGvEGFR compared
to U87MG cells [11]. However, this di¡erence was
quite small. Levels of phosphorylated ERKs in
U87MG cells were invariably higher than in
AG1478-treated U87MGvEGFR cells. This may be
due to antagonism of other ERK activation path-
ways by EGFRvIII. Montgomery et al. have re-
ported that EGFRvIII expressed in mouse ¢bro-
blasts inhibits ERK activation by phorbol ester and
serum [20], and provide evidence that the inhibition
is due to increased phosphatase activity.
We also compared the e¡ects of AG1478 on
EGFRvIII tyrosine phosphorylation with the e¡ects
on ERK phosphorylation. Analysis of total cell ex-
tracts by Western blotting with antibody to phospho-
tyrosine showed a identi¢ed a band of 140 000 kDa.
This band was absent in U87MGvEGFR cells
treated with AG1478 and in U87MG cells showing
that it corresponds to EGFRvIII. Tyrosine phos-
phorylation of EGFRvIII was inhibited by concen-
trations of AG1478 of 1 WM or higher. This corre-
lates well with the concentration of AG1478 required
to inhibit ERK phosphorylation in the same samples.
This, together with data described in the preceding
paragraphs, demonstrates clearly that EGFRvIII ac-
tivates ERKs in U87MGvEGFR cells.
EGFRvIII has previously been shown to constitu-
tively activate PI 3-kinase in 3T3 cells [21]. We also
assessed the activation of PI 3-kinase by EGFRvIII
in U87MGvEGFR cells, a more clinically-relevant
context. We used phosphorylation of PKB/akt at
serine 473 as a marker of PI 3-kinase activity, as
extensive research has shown that phosphorylation
at this site is dependent on PI 3-kinase activity (re-
viewed in [22]). Fig. 1 shows the serine-473 phos-
phorylation status of PKB/akt in U87MGvEGFR
cells and U87MG cells. Phosphorylated PKB/akt
was readily detected in U87MGvEGFR cells. PKB/
akt phosphorylation was blocked by treatment with
AG1478, and again the concentration of AG1478
that inhibited PKB/akt phosphorylation corre-
sponded well with the concentration that inhibited
EGFRvIII tyrosine phosphorylation (Fig. 1B).
PKB/akt phosphorylation was much lower or unde-
tectable in U87MG cells. Levels of total PKB protein
were the same in U87MGvEGFR cells and U87MG
cells, and were una¡ected by AG1478 treatment.
These results show that PI 3-kinase is constitutively
activated by EGFRvIII in glioblastoma cells.
3.2. EGFRvIII-induced ERK phosphorylation is
blocked by PI 3-kinase inhibitors
There have been reports that EGF receptor-medi-
ated activation of ERKs is partially blocked by PI 3-
kinase inhibitors in some cell types, but not in others.
We asked whether EGFRvIII-induced phosphoryla-
tion of ERKS was blocked by PI 3-kinase inhibitors.
U87MGvEGFR and U87MG cells were treated for
20 min with the PI 3-kinase inhibitor wortmannin at
a concentration of 100 nM, or with a second PI 3-
kinase inhibitor, LY294002, used at a concentration
of 50 WM. Analysis by Western blotting (Fig. 2)
showed that these treatments completely blocked
PKB phosphorylation without a¡ecting levels of to-
tal PKB protein, indicating that PI 3-kinase was ef-
fectively inhibited. The treatments also did not sig-
ni¢cantly a¡ect ERK protein levels (Fig. 2).
However, the amount of phosphorylated ERKs was
reduced to almost undetectable levels. In U87MG
cells, EGFRvIII-independent ERK phosphorylation
was also reduced by both PI 3-kinase inhibitors. It is
likely that the e¡ects of wortmannin and LY294002
seen in these experiments are due to direct inhibition
Fig. 2. PI 3-kinase inhibitor treatment in absence or presence
of EGF. U87MGvEGFR cells were treated with DMSO, 100
nM wortmannin (w) or 50 WM LY294002 (ly) for 20 min. Cells
in indicated lanes were also treated for 5 min with 100 ng/ml
EGF. (This was added for the last 5 min of the PI 3-kinase in-
hibitor treatment.) Total cell extracts were harvested and ana-
lyzed as in Fig. 1.
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of PI 3-kinase. Wortmannin has been shown to in-
hibit other kinases [23]. However, the IC50 values for
wortmannin inhibition of these enzymes are much
higher than the concentration of wortmannin used
here. Longer treatment (v 2 h) of U87MG and
U87MGvEGFR cells with wortmannin caused the
cells to round up and detach from the plate. This
was accompanied by a reactivation of ERKs, pre-
sumably secondary to these changes. For this reason,
we did not feel that inhibition of PI 3-kinase by
transfection of dominant negative versions of PI
3-kinase would provide useful information, as this
approach involves longer term (i.e., 1^2 days) expo-
sure of cells to PI 3-kinase inhibition.
3.3. ERK activation by normal EGFR in
glioblastoma cells
We next compared the activation of ERKs by
EGFRvIII in glioblastoma cells with ERK activation
by normal EGF receptor. U87MGvEGFR cells were
treated with PI 3-kinase inhibitors or DMSO control
as above, and then treated with 100 ng/ml EGF for
5 min to activate the normal EGF receptors present
in these cells. As shown in Fig. 2, none of these
treatments a¡ected overall levels of ERKs. EGF
treatment of U87MGvEGFR cells did induce an in-
crease in ERK phosphorylation above the levels seen
in untreated cells. However, preexposure of cells to
either wortmannin or LY294002 had little or no ef-
fect on the level of ERK phosphorylation seen in the
presence of 100 ng/ml EGF, although PKB phos-
phorylation was completely blocked with these treat-
ments. This is in marked contrast to the almost com-
plete inhibition of the ERK phosphorylation induced
by EGFRvIII. Similar results were obtained when
lower levels of EGF (10 or 1 ng/ml) were used
(data not shown). These data suggest that EGFRvIII
uses a signaling pathway for ERK activation that is
di¡erent from the pathway used by normal EGF
receptor activated by EGF.
3.4. Levels of activated EGFRvIII and normal EGFR
in glioblastoma cells
One possible explanation for this result comes
from previous observations that low concentrations
of activated EGF receptors activate ERK by a wort-
mannin-sensitive pathway, whereas high levels of ac-
tivated EGF receptor use a pathway that is predom-
inantly wortmannin-insensitive [15]. Analysis by £ow
cytometry shows that U87MG cells express 2U105
normal EGF receptors per cell and that the
U87MGvEGFR cells express between 4U105 and
2U106 EGFRvIII per cell [7,24]. EGFRvIII is there-
fore present at higher levels than wild-type EGF re-
ceptor in U87MGvEGFR cells. However, it has been
reported that not all EGFRvIII is tyrosine-phos-
phorylated in these cells. To directly compare levels
of activated receptors in U87MGvEGFR cells, we
analyzed Western blot samples for levels of EGF
receptor total protein and phosphotyrosine levels.
Analysis of samples with an antibody that recognizes
both normal EGF receptor and EGFRvIII (raised
against a sequence in the EGF receptor cytoplasmic
domain) show that levels of normal EGF receptor
(175 kDa) and EGFRvIII (two bands of approxi-
mately 150 and 140 kDa, as reported previously
[7]) were the same in each sample and were unaf-
fected by any of the treatments (Fig. 3). Analysis
of phosphotyrosine levels in EGFRvIII and normal
EGF receptor in U87MGvEGFR cells treated with
PI 3-kinase inhibitors showed that PI 3-kinase inhib-
itors had no e¡ect on the levels of phosphotyrosine
in EGFRvIII. Thus the blockade of EGFRvIII-in-
duced ERK phosphorylation by PI 3-kinase inhibi-
tors is not due interference with receptor tyrosine
phosphorylation. Treatment with EGF resulted in
the appearance of a higher molecular mass phospho-
Fig. 3. (A) Tyrosine phosphorylation of normal and mutant
EGF receptors. U87MGvEGFR cells were treated with DMSO,
wortmannin (w) or LY294002 (ly) as in Fig. 3. Cells in indi-
cated lanes were treated with EGF, also as in Fig. 3. Total cell
extracts were analyzed for phosphotyrosine, normal EGF recep-
tor and EGFRvIII by Western blotting.
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tyrosine-labeled band corresponding to normal EGF
receptor. In cells treated with EGF, we reproducibly
saw a small decrease in EGF receptor tyrosine phos-
phorylation when cells were preincubated with PI
3-kinase inhibitors. Although the mechanism for
this is unknown, it is possible that PI 3-kinase di-
rectly or indirectly regulates the activity of a phos-
photyrosine phosphatase that can use normal EGF
receptor as a substrate. The levels of phosphotyro-
sine in EGFRvIII and normal EGF receptor in cells
treated with PI 3-kinase inhibitors were very similar
under these experimental conditions. This shows that
the preferential use of a PI 3-kinase-sensitive path-
way by EGFRvIII is not due to a lower level of
activated EGFRvIII compared to activated normal
EGF receptor.
3.5. Role of MEK in ERK activation by EGFRvIII
Most studies have shown that ERK phosphoryla-
tion is directly mediated by the protein kinase MEK.
However, MEK-independent activation of ERK has
been described [25]. We tested whether ERK phos-
phorylation was inhibited by the speci¢c MEK inhib-
itor PD98059. We found that ERK phosphorylation
induced both by EGFRvIII and normal EGF recep-
tor was completely blocked by this inhibitor (Fig.
4A). From this it can be concluded that the di¡erent
ERK activation pathways used by normal and mu-
tant EGF receptors converge at or above the level of
MEK.
3.6. Role of phospholipase C in ERK activation by
EGFRvIII
We next assessed a possible role for phospholipase
C (PLC) in ERK activation by EGFRvIII.
U87MGvEGFR cells were treated for 15 min with
the aminosteroid phospholipase C inhibitor U73122
[26]. For controls, cells were treated with DMSO
alone, or with U73433, an inactive analogue of
U73122. This treatment has been shown to inhibit
80^90% of PLC-Q1 activity in CHO cells [27]. None
of the treatments a¡ected levels of total ERK pro-
tein. However, U73122 treatment did cause a marked
inhibition of ERK phosphorylation (Fig. 4B). This
inhibition was not seen with U73343, or with DMSO
alone. When normal EGF receptors in U87MG-
vEGFR cells were activated with EGF either in the
absence of presence of U73122, no di¡erences in the
level of ERK phosphorylation were observed.
3.7. E¡ects of conventional and novel protein kinase C
inhibitors on ERK activation by EGFRvIII
The results with the U73122 inhibitor suggested a
role for phospholipase C in activation of ERKs by
EGFRvIII. One way that phospholipase C could ac-
tivate ERKs would be by generation of the second
messenger diacylglycerol, which in turn could acti-
vate the conventional or novel PKC family members
[28]. There is extensive evidence that these PKCs can
activate ERKs, although the exact mechanism by
which this occurs is still not known. To determine
Fig. 4. E¡ects of MEK, phospholipase C and PKC inhibitors
on ERK phosphorylation. (A) U87MGvEGFR cells were
treated for 90 min with DMSO (lanes a,c) or the MEK inhibi-
tor PD98059 (at a ¢nal concentration of 50 WM). Cells in lanes
c and d were treated for 5 min with EGF. (B) U87MGvEGFR
cells were treated with DMSO (lanes a,d), U73433 (lanes b,e)
or U73122 for 15 min. Cells in lanes d^f were treated for 5 min
with EGF. (This was added for the last 5 min of the PLC in-
hibitor treatment.) (C) U87MGvEGFR cells were treated for
1 h with 0, 10, 100 or 500 nM of GOº 6976 (lanes a^d) or 0, 10,
100 or 500 nM of calphostin C (lanes e^h). Total cell extracts
were harvested and analyzed as in Fig. 1.
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if the conventional PKCs played a role in ERK acti-
vation by EGFRvIII, we treated cells with GOº 6976,
a selective inhibitor of PKCK and PKCLI [29]. We
saw no inhibition of ERK phosphorylation over a
range of inhibitor concentrations from 10 to 500
nM (Fig. 4C, lanes a^d). We also tested the e¡ect
of calphostin C, an inhibitor of both conventional
and novel PKCs that acts by inhibiting diacylglycerol
binding to these enzymes [30]. Again we saw no e¡ect
of this inhibitor over a range of concentrations from
0 to 500 nM (Fig. 4C, lanes e^h). These results sug-
gest that the neither the conventional nor novel PKC
enzymes have an essential role in ERK activation
induced by EGFRvIII.
4. Discussion
We have shown that both EGFRvIII and normal
EGF receptor induce the phosphorylation of ERKs
in glioblastoma cells. However, they appear to do so
by very di¡erent mechanisms. Thus EGFRvIII-in-
duced ERK phosphorylation was sensitive to two
di¡erent PI 3-kinase inhibitors, while ERK phos-
phorylation induced by EGF-activated normal
EGF receptor was insensitive to these inhibitors.
This di¡erence was seen under conditions where
amounts of activated normal and mutant EGF re-
ceptors were at a similar high level. Previous work by
others has shown that normal EGFR is able to acti-
vate ERKs by a wortmannin-sensitive pathway, but
only at very low levels of activated receptor [15].
There is considerable evidence that di¡erent kinetics
of ERK activation can result in completely di¡erent
cellular responses [13] and that di¡erent signaling
pathways are used to elicit these di¡erent kinetics
of activation [25]. Thus an understanding of the sig-
naling pathway used by EGFRvIII to activate ERKs
may help explain its potent ability to enhance tumor
growth in nude mice.
We also found that EGFRvIII activation of ERKs
was blocked by an inhibitor of PLC. Again this was
not seen with ERK activation by normal EGFR.
Although the inhibitor used here has not been dem-
onstrated to be speci¢c for PLC-Q1, this PLC would
seem likely to be the relevant target, given its well
known role in receptor tyrosine kinase signaling [31].
It has been shown that activation of PLC-Q1 involves
both the interaction of its src homology 2 domains
with receptor phosphotyrosine and also the interac-
tion of its pleckstrin homology domains with phos-
phatidylinositol 3,4,5-trisphosphate, the product of
PI 3-kinase. Inhibition of PI 3-kinase by wortmannin
blocks PLC-Q translocation to the plasma membrane
and partially blocks the production of inositol 1,4,5-
trisphosphate by this enzyme in cells treated with
PDGF [32]. Thus the inhibition of ERK phosphory-
lation by wortmannin in U87MGvEGFR cells might
be due, in part or in whole, to its inhibitory e¡ect on
PLC-Q activation.
PLC-Q catalyzes the production of the second mes-
sengers diacyglycerol and inositol 1,4,5-trisphos-
phate, with the latter inducing the release of calcium
from intracellular stores. This can in turn lead to
activation of either the conventional PKCs (activated
by Ca2 and diacyglycerol) or novel PKCs (activated
by diacylglycerol alone). Members of both these
PKC families are able to activate ERKs [33],
although the mechanism by which they do this is
not clear [34]. However, ERK activation induced
by EGFRvIII was not blocked by several di¡erent
PKC inhibitors that we tested, suggesting that these
enzymes do not mediate ERK activation by EGFR-
vIII. One possible explanation is that increases in
cytosolic Ca2 could activate ERKs via a pathway
other than the PKC pathway; as one possibility, the
Ca2/calmodulin-dependent protein kinases have
also been shown to mediate activation of ERKs in
some cell types [35]. However, we also have not ob-
served any inhibition of ERK phosphorylation when
U87MGvEGFR cells were treated with the Ca2/cal-
modulin dependent protein kinase inhibitor KN-621.
Alternatively, the e¡ects of U73122 could be due to
inhibition of some enzyme other than another PLC-
Q. ERK activation induced by engagement of integ-
rin/¢bronectin receptors has also been shown to re-
quire PI 3-kinase: this has been shown to be due to
PI 3-kinase-mediated activation of raf1 via p21-acti-
vated protein kinase [36]. We are currently investigat-
ing whether EGFRvIII also uses a similar pathway
to activate ERKs.
There are several possible reasons why EGFRvIII
might use a di¡erent pathway for ERK activation.
1 Lorimer and Lavictoire, unpublished observations.
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One possibility is that EGFRvIII preferentially het-
erodimerizes with another member of the erbB recep-
tor family in these cells. We feel this is unlikely, as it
has been reported that U87MG cells contain unde-
tectable levels of other erbB family members [37]. A
second possibility is that EGFRvIII adopts a di¡er-
ent conformation in its cytoplasmic domain that di-
rectly alters its a⁄nity for speci¢c adaptor molecules.
Several lines of evidence suggest that EGFRvIII
might adopt a di¡erent conformation of its cytoplas-
mic domain compared to normal EGFR: these in-
clude the fact that EGFRvIII is downregulated much
less rapidly than normal EGFR [9], and the reported
di¡erential sensitivity of EGFRvIII to tyrosine ki-
nase inhibitors compared to normal EGFR [19]. A
third possibility is that the slow internalization of
EGFRvIII [9] allows it to engage this pathway, while
normal EGFR is unable to engage this pathway e⁄-
ciently because of its rapid downregulation by inter-
nalization. This model implies that there are di¡er-
ences in the association and dissociation kinetics of
di¡erent adaptor proteins. Further studies comparing
the interaction of normal and mutant EGFR with
adaptor proteins should help to determine which of
these mechanisms is correct.
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